Company Description

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for the treatment of hypertension and other serious cardiovascular conditions. The company's lead clinical candidate, RTN-001, focuses on the treatment of patients with uncontrolled and resistant hypertension that have difficulty regulating blood pressure despite being on two to four other antihypertensive medications.